The present study was designed to determine the antimicrobial resistance and extended-spectrum b-lactamase (ESBL) activities of Klebsiella pneumoniae strains isolated from the neonatal intensive care unit of Atatürk University Hospital, Erzurum, Turkey. Antibiotic susceptibility of 40 isolates was detected by the standard disk diffusion method according to the National Committee for Clinical Laboratory Standards Guidelines. The double-disk synergy method was used to determine ESBL activity, which is associated with resistance to b-lactam antibiotics.
Introduction
Klebsiella pneumoniae is an important pathogen with the potential to cause severe morbidity and mortality in paediatric patients. 1 Extended-spectrum β-lactamase (ESBL) is an enzyme that confers resistance to aztreonam, cefotaxime, ceftazidime and related oxyimino-β-lactams, as well as to older penicillins and cephalosporins. 2 ESBL is most common in Klebsiella species and Escherichia coli, but is also present in a number of Enterobacteriaceae species. 3 The aim of this study was to determine the antimicrobial resistance of K. pneumoniae strains isolated from a neonatal intensive care unit and to establish the prevalence of ESBL. Although one study of antibiotic susceptibility and ESBL production of some Gram-negative rods from several sources in our hospital had been carried out previously, no study had focused on K. pneumoniae isolates from blood cultures of neonatal intensive care unit patients. Blood samples obtained aseptically were inoculated into paediatric culture bottles, and incubated in their respective automatic systems (Bactec 9240, Becton-Dickinson, Franklin Lakes, NJ, USA) for 7 days. During this period, if any signs of positivity appeared, subcultures were performed on McConkey agar and blood agar plates. Colonies on the agar plates were identified using the methods described above.
Materials and methods

BACTERIAL STRAINS
ANTIMICROBIAL SUSCEPTIBILITY TESTS
The antibiotic susceptibilities of the isolates were determined using the standard disk diffusion method described in the National Committee for Clinical Laboratory Standards Guidelines. 4 The double-disk synergy (DDS) test (Oxoid, Unipath Ltd, Basingstoke, UK) was used because it is simple, repeatable and reliable, as well as inexpensive. Strains that were shown to produce ESBL by DDS were confirmed by E-test (AB Biodisk, Solna, Sweden).
The organisms were suspended in Mueller-Hinton broth (Oxoid, Unipath Ltd, Basingstoke, UK) to a turbidity equal to the 0.5 McFarland turbidity standard. The suspension was used to inoculate Mueller-Hinton agar plates by swabbing. After inoculation, 30 µg disks of aztreonam, ceftazidime, ceftriaxone and cefotaxime were placed 30 mm and 20 mm (centre to centre) from an amoxicillin-clavulanate (20 µg and 10 µg, respectively) disk. After overnight incubation at 35 ºC, enhancement of the zone of inhibition between the clavulanate disk and any of the broadspectrum β-lactam disks confirmed the presence of an ESBL. 5
Results
Of the 40 isolates tested by DDS, enhanced zones of inhibition were observed with 24 isolates (60%). These isolates were considered to be ESBL-producing strains. All the strains tested were found to be resistant to ampicillin and sensitive to meropenem. Results of antibiotic susceptibility are shown in Table 1 .
Discussion
In recent years, bacterial resistance to β-lactam antibiotics has risen dramatically.
Contributing to this increase has been the spread of ESBLs, enzymes that hydrolyse the expanded-spectrum cephalosporins, such as ceftazidime and cefotaxime, and/or the monobactam aztreonam. 6, 7 Unfortunately, resistance to expandedspectrum cephalosporins is not detectable by routine susceptibility testing methods. 8 Additional tests are needed to detect strains that produce ESBL, the DDS method being one of the most simple and useful methods. 5 A number of studies have assessed the occurrence of ESBLs among the family Enterobacteriaceae. 6 -8 In the present study, 24 (60%) of the 40 K. pneumoniae strains were found to produce ESBL. In France, the reporter incidence of ESBL-producing bacteria is 30 -40% in strains isolated from patients with nosocomial infections, and 6% in those with other infections. 9 In the USA, it has been demonstrated that, on average, 8% of K. pneumoniae strains were ESBL producers. 9 Twenty-four per cent of the same bacteria strains in Greece have been found to express ESBL. 10 Reported ESBL-production rates in the K. pneumoniae strains from intensive care units of other countries are: 44% in Portugal; 31% in Belgium; 24% in France; 17% in Italy; 16% in Holland; 9% in Germany; and 1% in Spain. 11 In Turkey, the ESBL-production rates range from 11.0% to 86.6% in different centres. 12 This intra-country variation can be explained by a number of factors. First, Turkey is a large country, and the socioeconomic and cultural situations vary markedly between its regions. Secondly, studies to determine ESBL have been performed on samples from a wide variety of patient groups, and using a variety of different methods. Lastly, the duration of hospital stay and possible prior use of third-generation cephalosporins may be related to ESBL infections.
With the increasing emergence of antimicrobial resistance, which can vary between units within the same hospital and therefore poses a clinically significant risk to patients, particularly those in intensive care or high-dependency units, it is suggested that each hospital should determine its own resistance pattern. 13, 14 In a previous study of ESBL in the Atatürk University Hospital, 10 (41.6%) of 24 K. pneumoniae strains were defined as ESBL-producing bacteria. 15 Based on the results of the present study, which found that 60% of isolates were evaluated as ESBLproducing strains, it can be inferred that ESBL-producing K. pneumoniae strains are an increasing problem at this hospital. This study also found meropenem and ciprofloxacin to be the most effective drugs against K. pneumoniae strains, while ampicillin was the least effective. Meropenem is highly stable to β-lactamase hydrolysis. This has been confirmed by several clinical studies in which the
